Who
Stephen K. Brannan
Director
Company insider
Files Form 4 as: Director, Serina Therapeutics; Chief Medical Officer, Karuna Therapeutics.
In numbers
- Trades disclosed
- 194
- Buys
- 1
- Sells
- 32
- Bought
- $4,060
- Sold
- $40.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 14 Feb 2020
- Last trade
- 7 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 9 Jul 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,0301,000 at $2.03 | filing |
| 7 Jul 2026filed 9 Jul 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,0301,000 at $2.03 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 7 Nov 2025filed 10 Nov 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 22 May 2025filed 17 Jun 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $3.4M10,306 at $330.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $1.5M4,677 at $324.55 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $2.0M6,362 at $320.80 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $11.5M50,000 at $230.28 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $2.5M12,837 at $198.36 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $8.2M37,813 at $218.03 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $2.5M17,350 at $142.74 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code D | $11.9M36,117 at $330.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code D | $2.1M6,487 at $330.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code M | —3,209 at $0.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code M | —1,791 at $0.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code M | $14K2,500 at $5.45 | filing |
| 8 Mar 2024filed 11 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code M | $422K3,209 at $131.64 | filing |
News
Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Youngmanilatimes.net · 20 Oct 2026Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Stock Short Interest Report for SeptemberSER · tickerreport.com · 14 Oct 2026
1 headline in the last 90 days name Stephen K. Brannan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.